Jeffrey Crawford, MD

Professor of Medicine
George Barth Geller Distinguished Professor of Immunology
Member of the Duke Cancer Institute
Campus mail 443 Seeley G. Mudd Bldg, Durham, NC 27710
Phone (919) 681-9509
Email address

1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care


1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.

In Their Words

Education and Training

  • M.D., Ohio State University, 1974


Ramalingam, Sendhilnathan, Michaela A. Dinan, and Jeffrey Crawford. “Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States.” J Thorac Oncol 13, no. 12 (December 2018): 1842–50.

Full Text

Ahn, M. J., C. H. Chiu, Y. Cheng, J. Y. Han, S. B. Goldberg, A. Greystoke, J. Crawford, et al. “Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (November 1, 2018): ix151–52.

Full Text

Denduluri, Neelima, Gary H. Lyman, Yunfei Wang, Phuong Khanh Morrow, Richard Barron, Debra Patt, Debajyoti Bhowmik, et al. “Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer.” Clin Breast Cancer 18, no. 5 (October 2018): 380–86.

Full Text

Kinsey, Emily, Elizabeth Ajazi, Xiaofei Wang, Mary Ann Mayzie Johnston, and Jeffrey Crawford. “Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy.” J Thorac Oncol 13, no. 9 (September 2018): 1294–1301.

Full Text

Arantes, Luiz H., Jeffrey Crawford, Pere Gascon, Mark Latymer, Vincent Launay-Vacher, Catherine Rolland, Florian Scotte, and Jay Wish. “A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia.” Crit Rev Oncol Hematol 129 (September 2018): 79–90.

Full Text

Vlahovic, Gordana, Kellen L. Meadows, Ace J. Hatch, Jingquan Jia, Andrew B. Nixon, Hope E. Uronis, Michael A. Morse, et al. “A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.” Oncologist 23, no. 7 (July 2018): 782–90.

Full Text

Kinsey, Emily, Elizabeth Ajazi, Xiaofei F. Wang, Mary Ann Johnston, and Jeffrey Crawford. “The importance of body composition and physical function on overall survival (OS) in non-small cell lung cancer (NSCLC) patients receiving platinum based chemotherapy (PBCT).” In Journal of Clinical Oncology, 36:e21088–e21088. American Society of Clinical Oncology (ASCO), 2018.

Full Text

Cupp, Julia, Eva Culakova, Marek S. Poniewierski, David C. Dale, Gary H. Lyman, and Jeffrey Crawford. “Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia.” In Clin Lung Cancer, 19:e163–69, 2018.

Full Text